# Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.

> **NCT02849080** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 504 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** semaglutide
- **DRUG:** sitagliptin

## Key facts

- **NCT ID:** NCT02849080
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-20
- **Primary completion:** 2018-02-28
- **Final completion:** 2019-03-27
- **Target enrollment:** 504 (ACTUAL)
- **Last updated:** 2022-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02849080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02849080, "Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02849080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*